Efficacious Inhaled PDE4 Inhibitors with Low Emetic Potential and Long Duration of Action for the Treatment of COPD-Reference-Cited by-同舟云学术

Efficacious Inhaled PDE4 Inhibitors with Low Emetic Potential and Long Duration of Action for the Treatment of COPD

Published:2014-05-30 Issue:11 Volume:57 Page:4661-4676
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

De Savi Chris¹²,Cox Rhona J.¹³,Warner Daniel J.¹,Cook Anthony R.¹,Dickinson Mark R.¹,McDonough Amy¹⁴,Morrill Louis C.¹,Parker Beth¹,Andrews Glen¹,Young Simon S.¹⁴,Gilmour Peter S.¹⁴,Riley Rob¹⁴,Dearman Matthew S.¹³

Affiliation:

1. AstraZeneca R&D Charnwood, Loughborough, Leicestershire, LE11 5RH, U.K.

2. Oncology iMed, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States

3. Respiratory, Inflammation & Autoimmunity iMed, AstraZeneca R&D Mölndal, Pepparedsleden, 431 83 Mölndal, Sweden

4. AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, U.K.

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm5001216

Reference42 articles.

1. From theGlobal Strategy for the Diagnosis, Management, and Prevention of COPD;Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2014; available from:http://www.goldcopd.org/.

2. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study

3. The Top 10 Causes of Death;Fact Sheet no. 310;World Health Organization: Geneva,July 2013.

4. Projections of Global Mortality and Burden of Disease from 2002 to 2030

5. Delivering cost–effective care for COPD in the USA: recent progress and current challenges

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Designing inhaled small molecule drugs for severe respiratory diseases: an overview of the challenges and opportunities;Expert Opinion on Drug Discovery;2024-02-26

2. Phosphodiesterase inhibitors and lung diseases;Advances in Pharmacology;2023

3. Acid-Promoted Direct C–H Carbamoylation at the C-3 Position of Quinoxalin-2(1H)-ones with Isocyanide in Water;ACS Omega;2022-12-16

4. Medicinal chemistry strategies to extend duration of action of inhaled drugs for intracellular targets;Bioorganic & Medicinal Chemistry Letters;2022-04

5. Direct C3-H carbamoylation of quinoxalin-2(1H)-ones with isocyanides enabled by selectfluor II under mild conditions;Tetrahedron Letters;2022-01